Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the first quarter ended 30 April 2018 on 5 June 2018.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is currently conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)		[phone]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	[phone]
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	[phone]
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker)	Tel:	[phone]
Freddy Crossley
MacDougall Biomedical Communications (US)	Tel:	[phone]
Karen Sharma		[e-mail]
Consilium Strategic Communications (UK)	Tel:	[phone]
Mary-Jane Elliott / Jessica Hodgson /		[e-mail]
Lindsey Neville

-END-